Trial Profile

A Phase 2b Multicenter, Randomized, Placebo- Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Icotrokinra (Primary)
Indications Ulcerative colitis
Focus Therapeutic Use
Acronyms ANTHEM-UC
Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

10 Mar 2025 Results published in the Johnson & Johnson media release.
10 Mar 2025 Primary endpoint has been met. (Percentage of Participants with Clinical Response at Week 12), according to Johnson & Johnson media release.
07 Nov 2024 According to a Protagonist Therapeutics media release, top line results for the Phase 2b ANTHEM is expected in Q1 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com